KR20230044452A - 암을 치료하기 위한 bcl-2 억제제 및 저메틸화제의 조합물, 이의 용도 및 약학적 조성물 - Google Patents

암을 치료하기 위한 bcl-2 억제제 및 저메틸화제의 조합물, 이의 용도 및 약학적 조성물 Download PDF

Info

Publication number
KR20230044452A
KR20230044452A KR1020237006112A KR20237006112A KR20230044452A KR 20230044452 A KR20230044452 A KR 20230044452A KR 1020237006112 A KR1020237006112 A KR 1020237006112A KR 20237006112 A KR20237006112 A KR 20237006112A KR 20230044452 A KR20230044452 A KR 20230044452A
Authority
KR
South Korea
Prior art keywords
compound
day
azacytidine
treatment
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237006112A
Other languages
English (en)
Korean (ko)
Inventor
에멜린 데세인
리사 만케
마이클 로버트 쿠퍼
Original Assignee
르 라보레또레 쎄르비에르
노바르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 르 라보레또레 쎄르비에르, 노바르티스 아게 filed Critical 르 라보레또레 쎄르비에르
Publication of KR20230044452A publication Critical patent/KR20230044452A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020237006112A 2020-07-31 2021-07-30 암을 치료하기 위한 bcl-2 억제제 및 저메틸화제의 조합물, 이의 용도 및 약학적 조성물 Pending KR20230044452A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063059419P 2020-07-31 2020-07-31
US63/059,419 2020-07-31
EP20195633.1 2020-09-11
EP20195633 2020-09-11
PCT/EP2021/071368 WO2022023514A1 (en) 2020-07-31 2021-07-30 Combination of a bcl-2 inhibitor and a hypomethylating agent for treating cancers, uses and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
KR20230044452A true KR20230044452A (ko) 2023-04-04

Family

ID=77595496

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237006112A Pending KR20230044452A (ko) 2020-07-31 2021-07-30 암을 치료하기 위한 bcl-2 억제제 및 저메틸화제의 조합물, 이의 용도 및 약학적 조성물

Country Status (15)

Country Link
US (1) US20230270748A1 (https=)
EP (1) EP4188387A1 (https=)
JP (1) JP2023537290A (https=)
KR (1) KR20230044452A (https=)
CN (1) CN116390735A (https=)
AU (1) AU2021316674A1 (https=)
BR (1) BR112023001307A2 (https=)
CA (1) CA3190276A1 (https=)
CL (1) CL2023000242A1 (https=)
CR (1) CR20230046A (https=)
IL (1) IL300145A (https=)
JO (1) JOP20230013A1 (https=)
MX (1) MX2023001335A (https=)
PH (1) PH12023550205A1 (https=)
WO (1) WO2022023514A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025252168A1 (zh) * 2024-06-06 2025-12-11 苏州亚盛药业有限公司 一种含有Bcl-2/Bcl-xL抑制剂的药物组合及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3008975A1 (fr) 2013-07-23 2015-01-30 Servier Lab Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2017300738A1 (en) * 2016-07-22 2019-02-07 Les Laboratoires Servier Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof
UY38431A (es) 2018-10-31 2020-05-29 Servier Lab Formulación basada en ciclodextrina de un inhibidor de bcl-2
SI3873894T1 (sl) 2018-10-31 2023-08-31 Les Laboratoires Servier Nova sol Bcl-2 inhibitorja, z njo povezana kristalna oblika, postopek za pripravo le-teh in farmacevtski sestavki, ki jih vsebujejo

Also Published As

Publication number Publication date
CA3190276A1 (en) 2022-02-03
CN116390735A (zh) 2023-07-04
CR20230046A (es) 2023-04-11
WO2022023514A1 (en) 2022-02-03
IL300145A (en) 2023-03-01
MX2023001335A (es) 2023-04-27
BR112023001307A2 (pt) 2023-02-14
US20230270748A1 (en) 2023-08-31
CL2023000242A1 (es) 2023-11-10
PH12023550205A1 (en) 2024-06-24
EP4188387A1 (en) 2023-06-07
JP2023537290A (ja) 2023-08-31
JOP20230013A1 (ar) 2023-01-18
AU2021316674A1 (en) 2023-03-02

Similar Documents

Publication Publication Date Title
US12447171B2 (en) Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome
JP2024166290A (ja) 血液癌の併用療法
JP2022501394A (ja) Ｍｄｍ２阻害剤の医薬組成物、並びに疾患を予防及び／又は治療するためのその使用
WO2022090443A1 (en) Administration and dose regimen for a combination of a bcl-2 inhibitor and a mcl1 inhibitor
KR20220086627A (ko) 카페시타빈 및 트라스투주맙과 조합으로 투카티닙을 사용하여 her2 양성 유방암을 치료하는 방법
KR20230044452A (ko) 암을 치료하기 위한 bcl-2 억제제 및 저메틸화제의 조합물, 이의 용도 및 약학적 조성물
RU2746705C2 (ru) Комбинация bcl-2 ингибитора и mcl-1 ингибитора, их применения и фармацевтические композиции
US12514863B2 (en) Pharmaceutical combination and use thereof
JP7571024B2 (ja) 抗ｃｃｒ４抗体抵抗性のがんの治療剤
TWI753178B (zh) Mcl-1抑制劑與血液癌症標準療法之組合，其用途及醫藥組合物
JP2023512724A (ja) リンパ腫の治療におけるピリド［１，２－ａ］ピリミジノン化合物の使用
CN113509475A (zh) Bcl-2/bcl-xl抑制剂的组合及相关用途
US20220016118A1 (en) Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof
HK40092504A (zh) 治疗癌症的bcl-2抑制剂和低甲基化剂的组合、其用途和药物组合物
OA21163A (en) Combination of a BCL-2 inhibitor and a hypomethylating agent for treating cancers, uses and pharmaceutical compositions thereof.
US20240335440A1 (en) Combination therapy comprising a pkc inhibitor and a c-met inhibitor
TW202329968A (zh) 包含mdm2抑制劑、bcl2抑制劑和低甲基化劑的藥物組合及其用於治療血液惡性腫瘤之用途
WO2025124487A1 (zh) 含三氟甲基化合物和含呋喃并吡咯化合物的组合用于治疗血液肿瘤
HK40076724A (en) Methods of treating her2 positive breast cancer with tucatinib in combination with capecitabine and trastuzumab

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230221

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240723

Comment text: Request for Examination of Application